Osteoimmunology in rheumatoid arthritis
A comparison between conventional therapies and biologics
Keywords:
rheumatoid arthritis, osteoporosis, cytokines, antirheumatic agents, tumor necrosis factor inhibitorsAbstract
Aim: Rheumatoid arthritis is an immune-mediated disease that affects the peripheral joints and is characterized by chronic systemic inflammation with systemic bone mineral density loss. Susceptibility to osteoporosis occurs due to systemic inflammation, as well as chronic corticosteroid use. The biologic and target-specific disease-modifying antirheumatic drugs (DMARDs) act effectively blocking systemic inflammation. We hypothesized that patients receiving biologic and target-specific DMARDs have higher bone mineral density, exhibit lower serum pro-inflammatory cytokine levels, and require lower corticosteroid doses than those receiving conventional therapy. Methods: To test this hypothesis, we conducted a quantitative, descriptive, observational, cross-sectional and prospective clinical trial by collecting data from eligible patients. The participants were divided into three groups according to DMARD class (conventional synthetic, biologic, and target-specific DMARDs). The main inflammatory mediators of osteoporosis secondary to rheumatoid arthritis (tumor necrosis factor-α, interleukin-6), Disease Activity Score in 28 Joints, calculated using C-reactive protein, bone mineral density, bone turnover biomarker C-terminal telopeptide, and glucocorticoid dose were assessed in the three groups. Analysis of variance and Pearson product-moment correlation coefficient were used to compare the results among groups. Trial Registration Number - Certificate of Presentation for Ethical Consideration (CAAE): 46069821.4.0000.8667, 07/15/2021.
Downloads
References
Al-Bogami M, Bystrom J, Clanchy F, Taher TE, Mangat P, Williams RO, et al. TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20. Rheumatology (United Kingdom). 2021 Feb 1;60(2):947–57.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism. 2010;62(9):2569–81.
BRASIL. Protocolo clínico e diretrizes terapêuticas da artrite reumatoide [Internet]. Ministério da Saúde. Secretária de Atenção Especializada à Saúde. Secretária de Ciência, Tecnologia e Insumos Estratégicos. 2020 p. 1–194. Available from: http://conitec.gov.br/images/Consultas/Relatorios/2020/Relatrio_Artrite_Reumatoide_CP_21_2020.pdf
Buksman S, Angélica Pires Ferreira M, Corrêa Krug B, Beatriz Treter Gonçalves C, Medeiros Amaral K, Costa Xavier L, et al. Protocolo Clínico e Diretrizes Terapêuticas, Osteoporose, Portaria SAS/MS no 451, de 9 de junho de 2014, republicada em 9 de junho de 2014 e retificada em 18 de junho de 2014. 2014;22. Available from: http://portalarquivos2.saude.gov.br/images/pdf/2014/dezembro/15/Osteoporose.pdf
Bultink IEM, Vis M, van der Horst-Bruinsma IE, Lems WF. Inflammatory rheumatic disorders and bone. Current Rheumatology Reports. 2012;14(3):224–30.
Chen JF, Hsu CY, Yu SF, Ko CH, Chiu WC, Lai HM, et al. The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis. Rheumatology. 2020;1–10.
Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis. 2017 Dec 1;12(1).
Fardellone P, Salawati E, le Monnier L, Goëb V. Bone Loss, Osteoporosis, and Fractures in Patients with Rheumatoid Arthritis: A Review. Journal of Clinical Medicine. 2020;9(10):3361.
Geusens P, Lems WF. Osteoimmunology and osteoporosis. Arthritis Research and Therapy. 2011;13(5):1–16.
Gulyás K, Horváth Á, Végh E, Pusztai A, Szentpétery Á, Pethö Z, et al. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clinical Rheumatology. 2020;39(1):167–75.
Kanis JA, Johnell O, Oden A, Johansson H, Mccloskey E. FRAXTM and the assessment of fracture probability in men and women from the UK.
Lee SH, Kim TS, Choi Y, Lorenzo J. Osteoimmunology: Cytokines and the skeletal system. Journal of Biochemistry and Molecular Biology. 2008;41(7):495–510.
Loures MAR, Zerbini CAF, Danowski JS, Pereira RMR, Moreira C, Paula AP de, et al. Diretrizes da Sociedade Brasileira de Reumatologia para diagnóstico e tratamento da osteoporose em homens. Revista Brasileira de Reumatologia. 2017;57(S 2):497–514.
Orsolini G, Fassio A, Rossini M, Adami G, Giollo A, Caimmi C, et al. Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis. Vol. 147, Pharmacological Research. Academic Press; 2019.
Pinheiro MM, Ciconelli RM, Jacques N de O, Genaro PS, Martini LA, Ferraz MB. O impacto da osteoporose no Brasil: dados regionais das fraturas em homens e mulheres adultos - The Brazilian Osteoporosis Study (BRAZOS). Revista Brasileira de Reumatologia. 2010;50(2):113–20.
Radominski SC, Bernardo W, Paula AP de, Albergaria BH, Moreira C, Fernandes CE, et al. Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós‐menopausa. Revista Brasileira de Reumatologia. 2017;57(S 2):452–66.
Raterman HG, Lems WF. Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide. Drugs and Aging [Internet]. 2019;36(12):1061–72. Available from: https://doi.org/10.1007/s40266-019-00714-4
Rossini M, Adami G, Viapiana O, Idolazzi L, Orsolini G, Fassio A, et al. Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis? Journal of Bone and Mineral Research. 2017;32(10):2142–3.
Smolen JS. Treat-to-target as an approach in inflammatory arthritis. Vol. 28, Current Opinion in Rheumatology. Lippincott Williams and Wilkins; 2016. p. 297–302.
Sousa C de J, Oliveira MLC de, Sousa C de J, Oliveira MLC de. FRAX Tool in Brazil: an integrative literature review following validation. Revista Brasileira de Geriatria e Gerontologia [Internet]. 2018 Feb [cited 2020 Jul 15];21(1):108–15. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1809-98232018000100108&lng=en&tlng=en
Srivastava RK, Dar HY, Mishra PK. Immunoporosis: Immunology of osteoporosis-role of T cells. Frontiers in Immunology. 2018;9(APR):1–12.
Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nature Reviews Rheumatology [Internet]. 2009;5(12):667–76. Available from: http://dx.doi.org/10.1038/nrrheum.2009.217
Takayanagi H. Osteoimmunology as an intrinsic part of immunology. Vol. 33, International Immunology. Oxford University Press; 2021. p. 673–8.
Tomizawa T, Ito H, Murata K, Hashimoto M, Tanaka M, Murakami K, et al. Distinct biomarkers for different bones in osteoporosis with rheumatoid arthritis. Arthritis Research and Therapy. 2019;21(1):1–9.
Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2006;65(11):1495–9.
Wang Y, Zhao R, Gu Z, Dong C, Guo G, Li L. Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis. Osteoporosis International. 2020;31(8):1401–9.
Wysham KD, Baker JF, Shoback DM. Osteoporosis and fractures in rheumatoid arthritis. Vol. 33, Current opinion in rheumatology. NLM (Medline); 2021. p. 270–6.
Yoshii I, Chijiwa T, Sawada N. Rheumatoid arthritis in tight disease control is no longer risk of bone mineral density loss. Osteoporosis and Sarcopenia. 2020 Jun;6(2):75–81.
Zanchetta J. Epidemiologia, custos e ônus da osteoporose em 2012. International Osteoporosis Foundation. 2012;28.
Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Uña CR, et al. Biologic therapies and bone loss in rheumatoid arthritis. Osteoporosis International. 2017;28(2):429–46.
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
